Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

44.96 -0.46 (-1.01%)

Streaming Delayed Price Updated: 12:04 PM EDT, Aug 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

42 43 Next >

Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

December 06, 2023

SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Investor Demand for Clarity Grows Amid Sanofi's Strategic R&D Shift ↗

December 05, 2023

Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget.

Via Benzinga

Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers ↗

December 01, 2023

European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies...

Via Benzinga

How Is The Market Feeling About Sanofi? ↗

November 30, 2023

Via Benzinga

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment

November 30, 2023

From Teva Pharmaceutical Industries Limited

Via Business Wire

Is NASDAQ:SNY a Good Fit for Dividend Investing? ↗

November 21, 2023

Is SANOFI-ADR (NASDAQ:SNY) a Good Fit for Dividend Investing?

Via Chartmill

Looking Into Sanofi's Recent Short Interest ↗

November 13, 2023

Via Benzinga

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

November 30, 2023

These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.

Via The Motley Fool

Teva Pharma is the way to play the re-rise of generic drugs

November 28, 2023

Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth

Via MarketBeat

Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales ↗

November 27, 2023

Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation.

Via Investor's Business Daily

Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder ↗

November 27, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that...

Via Benzinga

Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease

November 27, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

This Stock Just Dropped By 15%: Is It a Buy? ↗

November 03, 2023

Now could be a great opportunity to buy low.

Via The Motley Fool

Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst ↗

November 22, 2023

Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the

Via Benzinga

US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges ↗

November 17, 2023

The U.S.

Via Benzinga

Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B ↗

November 16, 2023

Sanofi SA (NYSE: SNY) has reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over...

Via Benzinga

Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

November 15, 2023

SANOFI-ADR (NASDAQ:SNY) is an undervalued gem with solid fundamentals.

Via Chartmill

MarketBeat Week in Review – 11/6 - 11/10

November 11, 2023

Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week

Via MarketBeat

Topics Artificial Intelligence Economy

Is NASDAQ:SNY a Good Fit for Dividend Investing? ↗

October 31, 2023

Is SANOFI-ADR (NASDAQ:SNY) a Good Fit for Dividend Investing?

Via Chartmill

Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week ↗

October 30, 2023

S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.

Via Benzinga

Topics Economy Stocks

Pfizer and Sanofi shares fall, which one to scoop up?

November 07, 2023

Pharmaceutical stocks aren't having a banner year; notably, two large pharmaceutical companies recently plunged to 52-week lows

Via MarketBeat

Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi ↗

November 06, 2023

The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases.

Via Investor's Business Daily

Get Ready for Next Generation of Diabetes, Weight-Management Drugs

November 01, 2023

Via Investor Brand Network

Get Ready for Next Generation of Diabetes, Weight-Management Drugs

November 01, 2023

EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END

Via FinancialNewsMedia

Investor patience tested as pharmaceutical stocks take a tumble

November 01, 2023

The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector

Via MarketBeat

Why Is Gene Therapy Company MeiraGTx Stock Trading Higher Today? ↗

October 30, 2023

MeiraGTx Holdings plc (NASDAQ: MGTX) shares are trading higher after French pharma giant Sanofi SA (NASDAQ: SNY) made a $30 million

Via Benzinga

Sanofi (SNY) Q3 2023 Earnings Call Transcript ↗

October 27, 2023

SNY earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 27, 2023

Via Benzinga

Stock Market Correction Intensifies; Google, Meta, Microsoft, Amazon Are Big Earnings Movers: Weekly Review ↗

October 27, 2023

Microsoft, Google, Amazon and Meta led big earnings.

Via Investor's Business Daily

Why Barnes Group Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

October 27, 2023

Gainers Apollomics, Inc. (NASDAQ: APLM) shares surged 88.4% to $1.07 stoma multiforme with PTPRZ-MET fusion.

Via Benzinga

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.